Effect of Sepia on Menopausal complaints in women

Sepia in Menopausal Symptoms: A Multi-centre Randomized Double Blind Placebo Controlled Clinical Trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2011/12/002269

Enrollment

Registered

2011-12-22

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Menopause

Interventions

Intervention1: Sepia 200: Sepia 200 , 2 doses at monthly interval for 6 months Control Intervention1: Placebo: Identical placebo, 2 doses at monthly interval for 6 months

Eligibility

Inclusion criteria

Inclusion criteria: ? Perimenopausal women between 40 to 55 years of age with history of menopausal symptoms for at least one month within the last one year. ? Signed the informed consent form. ? Sepia should be indicated after thorough case taking, repertorization along with justification of prescription. ? Subsequent investigations should not exclude the patient. ? If the patient is under any treatment for the menopausal complaints or taking oral contraceptives, she can be included only after the washout period of 15 days. In case, the patient is on HRT, she should have withdrawn HRT for at least 2 months before inclusion.

Exclusion criteria

Exclusion criteria: ? The women with symptoms not corresponding to the Sepia. ? Women with established menopause either natural or artificial. ? DUB (Dysfunctional uterine bleeding) /history of endometrial hyperplasia/ malignancy. ? Women on long term medication for any disease. ? Women with history of severe psychiatric disturbance. ? Women presenting with history of systemic illnesses, hypertension, diabetes mellitus, cardio/cerebro-vascular diseases, pelvic pathology requiring surgery, any malignancy. ? Women using any medicine or supplement containing estrogen, progestin etc. ? Any case deemed unfit for inclusion by the investigator. ? Patient not willing to sign the written informed consent.

Design outcomes

Primary

Measure	Time frame
The Greene Climacteric ScaleTimepoint: The Greene Climacteric Scale will be assessed at 6 months after enrollment.	—

Secondary

Measure	Time frame
Utian Quality of Life Scale (UQOL)Timepoint: Utian Quality of Life Scale (UQOL)shall be filled up at baseline and at 6 months	—

Countries

India

Contacts

Public ContactDr Jaya Gupta

Central Council for Research in Homoeopathy

jgupta21@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026